Related Experiment Video
Updated: Dec 11, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better
Gabriella Pietra1,2, Maria Cristina Mingari3,2, Lorenzo Moretta4
1Department of Experimental Medicine (DiMES), Università di Genova, Genoa, Italy.
Abstract:
IL15 and TIGIT blockade enhances the natural killer (NK) cell-mediated activity against MHC-I-deficient melanoma both in vitro and in preclinical models. IL15-induced harnessing of NK cells, associated with their unleashing by TIGIT blockade, may represent a therapeutic approach for tumors, which lack HLA-I molecules thus escaping the CD8+ T cell-mediated control.See related article by Chauvin et al., p. 5520.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment

